INDEX

Note: Page numbers of article titles are in boldface type.

Accuprobes, in mycobacterial diseases, 368
Acquired immunodeficiency syndrome (AIDS), mycobacterial infection in, 359
prevalence, 203
Adult respiratory distress syndrome (ARDS), ventilator-associated
pneumonia in, 296
Agar dilution tests, for bacteria that grow aerobically, 397
Agar screen, in detection of methicillin-resistant staphylococci, 428
AIDS, mycobacterial infection in, 359
prevalence, 203
Airways, distal, in ventilator-associated pneumonia, 306–308
proximal, in ventilator-associated pneumonia, 303–306
Anaerobe culture, indications, 257
Anaerobes, culture and identification of, reasons for, 262–264
Anaerobic bacteriology, approaches to, 264–265
current issues in, 260–262
Anaerobic infections, as clues to other problems in patients, 259–260
current perspectives on, 257–275
diagnosis, 257–258, 260–268
delayed culture reports, 261
financial constraints, 261
improperly collected and handled specimens, 261
primary inoculation in, 265–268
taxonomy in, 262
examples, 258
nature of, underlying clinical conditions as clues to, 260
susceptibility testing for, 268–273
breakpoints in, 270
clustering of MICs about, 269
clinical correlation, 273
endpoint determination in, 270
mechanisms of resistance to antimicrobial agents, 270–273
media in, 269
methods, 268–269
values chosen for reporting, 270
Anaerobiosis, by simple methods, 266
Antibiotic removal device (ARD), in blood culture analysis, 225
Antibodies, HIV, screening for, 204–207
supplementary tests for, 208–210
Antifungal susceptibility testing, 435–444.
See also Susceptibility testing, antifungal.
Antigen, HIV-1 p24, detection of, 210–211
in Legionella infections, 384–385
Antimicrobial agents, anaerobe susceptibility to, 271–272
mechanisms of resistance to, in anaerobic infections, 270–273
susceptibility testing for, 393–395
future directions in, 406–407
interpretation of results, 403–404
methods, 395–401
selection of, 404–406
quality control procedures in, 401–403
in ventilator-associated pneumonia, 349–351
in ventilator-associated pneumonia, 323–324
Antiviral susceptibility tests, in viral disease diagnosis, 191–193
ARDS. See Adult respiratory distress syndrome.

Bacilli. See also β-Lactamases.
nonfastidious gram-negative, detection of, future directions in, 420–422
β-lactam resistance among, predictor panel in, 418–420
β-lactam resistance among, detection of, 411–424
BacT/Alert, 229–230
BACTEC 660/730/860 nonradiometric systems, 229
BACTEC 460 radiometric system, 229
BACTEC radiometric system, detection
from blood, 229
in mycobacterial diseases, 359, 367
Bacteremia, defined, 222
transient, defined, 222
Bacteria, cell wall deficient forms of,
detection from blood, 228
nutritionally fastidious, testing of, 398
probe kits for, 175
in ventilator-associated pneumonia, 300–
301, 341–346
Bactericidal testing, 445–459
antibiotic carryover during, 451
biological considerations in, 446–450
determination and calculation of end-
points in, 451
emergence of resistance in, 449
growth phase in, 450
history of, 445–446
incubation conditions during, 451
inoculum effect of, 447–448
inoculum size in, 450
insufficient contact during, 450–451
killing rate in, 446
media in, 450
minimal bactericidal concentration in,
446
paradoxical effect of, 447
persisters in, 447
pharmacodynamic parameters in, 446–
448
postantibiotic effect in, 446–447
procedures, 452–453
rationale for, 445–446
serum, 452–453
species-specific bactericidal activity in,
449–450
technical considerations in, 450–452
time-kill kinetic assay in, 453
tolerance in, 448
Bacteriology, anaerobic, approaches to,
264–265
current issues in, 260–262
BAL. See Bronchoalveolar lavage.
Blood culture, 221–234
atmosphere and duration of incubation, 226
basic concepts, 221–222
blood-to-broth ratio and neutralization
methods, 225–226
culture medium, 225
defined, 221
determination of contamination versus
true bacteremia and fungemia, 230–
231
indications, 222
limitations, 226
microorganisms requiring special media,
226–229
number of, 223–224
obtaining of, 222–223
timing of, 223
venipuncture site, 222–223
volume of, 224
Blood culture systems, 229–230
Blood cultures, in ventilator-associated
pneumonia, 301–303
Blood specimens, in viral disease diagnosis,
185–186
Bronchial washing, in ventilator-associated
pneumonia, 309
Bronchoalveolar lavage (BAL),
nonbronchoscopic, in ventilator-
associated pneumonia, 307–308
in pneumonia, 295
protected, in ventilator-associated pneu-
monia, 317–318
in ventilator-associated pneumonia, 314–
317
in viral disease diagnosis, 185–186
Bronchoscopy, fiberoptic, in ventilator-
associated pneumonia, 308–309
in ventilated patients, risk of, 318–319
Broth dilution, in detection of methicillin-
resistant staphylococci, 427–428
Broth dilution tests, for bacteria that grow
aerobically, 395–397
Brucella, detection from blood, 227

C5a peptidase, in group A streptococci, 240
Cell cultures, in viral disease diagnosis,
186–187
Chromatography, direct, in detection of
Clostridium difficile diarrhea, 283
gas liquid, in mycobacterial diseases,
368–369
high-performance liquid, in mycobacte-
rial diseases, 368–369
Clostridium difficile diarrhea. See Diarrhea,
Clostridium difficile.
Clostridium difficile protein, latex test for,
282–283
CMV. See Cytomegalovirus.
Counterimmunoelectrophoresis, in
detection of Clostridium difficile
diarrhea, 283
Culturette CDT test, in detection of
Clostridium difficile diarrhea, 282–283
Cytomegalovirus (CMV) antigenemia, 188–
190
Cytotoxin assay, in detection of Clostridium
difficile diarrhea, 279–281
Diarrhea, *Clostridium difficile*, causes, 277
diagnosis, 277, 277–293
laboratory detection of, 279–286
counterimmunoelectrophoresis in, 283
culture in, 281–282
current approach to, 285–286
cytotoxin assay in, 279–281
direct chromatography in, 283
enhanced organism detection in, 287
future direction for, 285–286
Gram stain in, 279
immunoassays for, 283, 284
laboratory support for infection control, 286–288
latex test for, 282–283
specimen collection and transport in, 279
susceptibility testing in, 288
populations at risk for, 278–279
typing of *Clostridium difficile* in, 287–288
Direct chromatography, in detection of *Clostridium difficile* diarrhea, 283
Disk diffusion, in detection of methicillin-resistant staphylococci, 427
Disk diffusion tests, for bacteria that grow aerobically, 397–398
Distal airways, in ventilator-associated pneumonia, 306–308
DNA hybridization, technique, clinical utility of, 178
in infectious disease diagnosis, 171–181
new technology, 178
nucleic acid amplification assays, 177–178
probe kits for, 174–176
in situ hybridization, 176
DNA probe tests, in ventilator-associated pneumonia, 346
Dot-blot method, in detection of methicillin-resistant staphylococci, 429

ELISA. See *Enzyme-based immunoassay (ELISA) antibody tests.*
Enterococcal infections, 247–250
Enzyme-linked immunosorbent assay (ELISA) antibody tests, in HIV infection, 204–206
in mycobacterial diseases, 370
in viral disease diagnosis, 190–191
ESP Blood Culture System, 230

Fever, in ventilated patients, 298
Fluorescent antibody (FA) stains, in ventilator-associated pneumonia, 342–346

Fungal infections, susceptibility testing for, 435–444. See also *Susceptibility testing, antifungal.*
Fungemia, in immunocompromised patients, 228–229
Fungi, detection from blood, 228–229
mold, antifungal susceptibility testing of, 441
probe kits for, 176

Gas liquid chromatography (GLC), in mycobacterial diseases, 368–369
Gene(s), antimicrobial resistant, probe kits for, 175–176
Gene amplification, HIV, 212–214
Gram stain, in detection of *Clostridium difficile* diarrhea, 279

High-performance liquid chromatography, in mycobacterial diseases, 368–369
HIV–1 Accusearch detection system, 214
HIV infection. See *Human immunodeficiency virus (HIV) infection.*
Human immunodeficiency virus (HIV) infection, antibodies associated with, screening for, 204–207
supplementary tests for, 208–210
described, 203–204
ELISA in, 204–206
gene amplification, 212–214
isolation of, in cell culture, 211–212
laboratory diagnosis, 203–219
polymerase chain reaction in, 213
prevalence, 203
rapid antibody tests in, 207
symptoms, 206
Human immunodeficiency virus type–1 (HIV–1) infection, Western blot, 208–210
Human immunodeficiency virus type–2 (HIV–2) infection, and combination HIV–1/HIV–2 antibody tests, 207
Human immunodeficiency virus type–1 (HIV–1) infection p24 antigen, detection of, 210–211
Hybridization, defined, 173–174

Imunoassays, for *Clostridium difficile* diarrhea, 283, 284
enzyme, in viral disease diagnosis, 190–191
in ventilator-associated pneumonia, 346
Immunofluorescence assay (IFA), indirect, in HIV infection, 210
Infection, anaerobic, 257–275. See also Anaerobic infections.
Infectious disease(s), laboratory diagnosis, DNA hybridization techniques, 171–181
issue on, 171–459
Isolator system, 225–226, 230
in mycobacterial diseases, 367
Laboratory diagnosis, of infectious diseases, issue on, 171–459. See also specific disease.
β-Lactam drug-β-lactamase inhibitor combinations, among nonfastidious gram-negative bacilli, 414–415
β-Lactam resistance, among nonfastidious gram-negative bacilli, 411–424. See also Bacilli, nonfastidious gram-negative.
β-Lactamases, extended spectrum, among nonfastidious gram-negative bacilli, 414
inducible, among nonfastidious gram-negative bacilli, 412–413
Latex agglutination test, in detection of Clostridium difficile diarrhea, 282–283
Legionella, 377–392
classification, 377–382
detection from blood, 227
identification of, 377–382
species of, 378
Legionella infection, diagnosis, 382–385
culture in, 382–384
detection of antigen and nucleic acids in, 384–385
serology in, 384
microbiologist’s role in, 385–387
Leptospira, detection from blood, 227
Lung biopsy, open, in ventilator-associated pneumonia, 349
Lysis-Centrifugation system, 225–226, 230
M protein, in group A streptococci, 239–240
mecA detection tests, in detection of methicillin-resistant staphylococci, 429–430
Methicillin resistance, mechanisms of, 426–427
Microscopy, in ventilator-associated pneumonia, 340–346
Minimal bactericidal concentration (MBC), in bactericidal testing, 446
microdilution, in bactericidal testing, 452
Mold fungi, antifungal susceptibility testing of, 441
Mycobacteria, commonly isolated, 361–362
detection from blood, 228
with unusual growth requirements, 362–364
Mycobacterial diseases, AIDS and, 359
classification, 360–361
laboratory diagnosis, 359–376
BACTEC radiometric system in, 359
culture methodology, 366–367
identification methodology, 367–369
specimen selection, collection, processing, and staining, 365–366
strain tracking in, 370–371
susceptibility testing in, 371–372
techniques in development, 369–370
taxonomy, 360–361
Mycobacterium, M. avium, described, 361–362
M. chelonae, described, 362
M. fortuitum, described, 362
M. genavense, unusual growth requirements of, 363
M. gordonae, described, 362
M. haemophilum, unusual growth requirements of, 363
M. intracellulare, described, 361–362
and the “X” cluster, described, 361–362
M. kansasii, described, 362
M. marinum, unusual growth requirements of, 363
M. malmoense, unusual growth requirements of, 363
M. tuberculosis, described, 361
M. tuberculosis complex, described, 361
M. ulcerans, unusual growth requirements of, 364
M. xenopi, unusual growth requirements of, 364
NAP test, in mycobacterial diseases, 368
National Committee for Clinical Laboratory Standards (NCCLS), antifungal susceptibility testing activities of, 437–440
National Committee for Clinical Laboratory Standards (NCCLS) reference protocol, for anaerobic infections, 268
Neutralization methods, in blood culture analysis, 225–226
Nucleic acid, in Legionella infections, 384–385
INDEX

465

in viral disease diagnosis, 194
Nucleic acid amplification, defined, 172
Nucleic acid amplification assays, in DNA
hybridization, 177–178
Nucleic acid probes, defined, 172
in viral disease diagnosis, 194

Open-lung biopsy, in ventilator-associated
pneumonia, 319–320, 349

Persisters, in bactericidal testing, 447
defined, 447
Plugged telescoped catheter sampling,
nonbronchoscopic, in ventilator-
associated pneumonia, 308
Pneumonia, bacterial, BAL culture in, 315
defined, 300
described, 295
diagnosis, 295
nosocomial, 296
ventilator-associated, in ARDs, 296
bacteria in, 300–301
causes, 332
characteristics, 331
diagnosis, 295–329
BAL in, quantitative cultures of, 337
blood cultures in, 301–303
bronchoscopic techniques in, 308–319
clinical, 296–301
invasive procedures, 308–320
microbiologic, 331–357
culture procedures, 347–351
DNA probe tests in, 346
immunoassay tests in, 346
methods, 338–339
new directions in, 352–353
organism detection in, 341–346
serology in, 351
smear preparation in, 340
specimen handling in, 339
specimen quality in, 340–341
specimen selection in, 333–338
nonbronchoscopic BAL in, 307–308
nonbronchoscopic plugged tele-
coped catheter sampling in, 308
nonbronchoscopic protected speci-
men brushing in, 307
noninvasive procedures, 301–308
open-lung biopsy, 319–320
recommendations for, 322–324
sampling of the proximal airways in, 303–306
sampling of the distal airways in, 306–308

Polymerase chain reaction (PCR),
described, 171
in detection of methicillin-resistant
staphylococci, 429–430
in HIV infection, 213
schematic diagram of, 173
in viral disease diagnosis, 194–197
Probe kits, in DNA hybridization, 174–176
to antimicrobial resistance genes, 175–176
for bacteria, 175
to fungi, 176
for respiratory pathogens, 174
for screening urine samples, 176
for sexually transmitted disease agents,
174–175
for strain typing, 175
for throat swabs, 176
Probes, nucleic acid, defined, 172
in viral disease diagnosis, 194
Protected BAL, in ventilator-associated
pneumonia, 317–318
Protected specimen brushing,
nonbronchoscopic, in ventilator-
associated pneumonia, 307
in ventilator-associated pneumonia, 309–313
Protein, Clostridium difficile, latex test for, in
detection of Clostridium difficile
diarrhea, 282–283
Proximal airways, in ventilator-associated
pneumonia, 303–306
Pyrogenic exotoxins, in group A
streptococci, 240–242

Rapid antibody tests, in HIV infection, 207
Respiratory secretions, sampling of,
methods, 299
Rochalimaea, detection from blood, 227
Roche Amplicor system, 213

Septicemia, defined, 221–222
prevalence, 221
Serology, in Legionella infections, 384
in ventilator-associated pneumonia, 351
in viral disease diagnosis, 193
Serotyping, in mycobacterial diseases, 370–371
Serum bactericidal test, 452–453
Sexually transmitted diseases, pathogens
of, probe kits for, 174–175
Shell vial assay, in viral disease diagnosis,
187–188
Sodium polyanetholesulfonate (SPS), in blood culture analysis, 225
Specimen brushing, nonbronchoscopic protected, in ventilator-associated pneumonia, 307
protected, in ventilator-associated pneumonia, 309-313
Speti-Check AFB system, in mycobacterial diseases, 367
Sputum, described, 295
expectorated, in ventilator-associated pneumonia, 303-304
Staphylococci, methicillin-resistant, causes, 426-427
detection of, 425-433
dot-blot method in, 429
mecA tests in, 429-430
polymerase chain reaction in, 429-430
susceptibility testing in, 427-429
Streptococcal infections, group A, detection from swabs, 239
Streptococcus pyogenes in, 242-244
typing of, 242-244
virulence factors of, 239-242
group B, 245-246
detection from swabs, 239
group C, 246-247
group D, 247-250
group G, 246-247
β-hemolytic, diagnosis, 235-256
collection, transport, and processing of specimens in, 236
identification of specimens in, 237-239
Streptococci, nutritionally variant, detection from blood, 227-228
Streptococcus agalactiae, in group B streptococcal infections, 245-246
Streptococcus pyogenes, in group A streptococcal infections, 242-244
Susceptibility testing, in anaerobic infections, 268-273
antifungal, 435-444
of mold fungi, 441
NCCLS subcommittee activities concerning, 437-440
in vitro, 436-442
clinical correlation of test results, 441-442
rationale for, 436
standardization of, 436-437
variables in, 436
antimicrobial, of bacteria that grow aerobically, 393-409
automated instrument methods in, 398-399
future directions in, 406-407
interpretation results, 403-404
methods, 395-401
selection of, 404-406
novel test methods, 400-401
quality control procedures in, 401-403
rationale for, 393
in ventilator-associated pneumonia, 349-351
in Clostridium difficile diarrhea, 288
in detection of methicillin-resistant staphylococci, 427-429
in mycobacterial diseases, 371-372
in viral diseases, 191-193

Time-kill kinetic assay, in bactericidal testing, 453
Tolerance, defined, 448
Tracheal aspirate, in ventilator-associated pneumonia, 304-306, 335
Tuberculostearic acid, in mycobacterial diseases, 369

Venipuncture, for blood culture, site of, 222-223
Ventilators, patients on, fever and pulmonary infiltration in, 298
pneumonia due to, 295-329. See also Pneumonia, ventilator-associated.
Viral diseases, diagnosis, antiviral susceptibility tests in, 191-193
BAL in, 185-186
blood specimens in, 185-186
cell cultures in, 186-187
CMV antigenemia in, 188-190
enzyme immunoassays in, 190-191
new developments in, 183-201
nucleic acid detection methods in, 194
nucleic acid probes in, 194
polymerase chain reaction in, 194-197
serology in, 193
shell vial assay in, 187-188
significance of test results, 184-185
specimen collection and transport in, 184
virus isolation patterns in, 184-185